Further analysis of the Phase III KODIAC-04, KODIAC-05 and KODIAC-08 studies showed that Movantik (naloxegol), from AstraZeneca, had a similar...
AstraZeneca announced a co-commercialisation agreement with Daiichi Sankyo, Inc. for Movantik (naloxegol) in the USA. Under the terms of the...
AstraZeneca has announced that the FDA approved Movantik (naloxegol) tablets C-II as the first once-daily oral peripherally-acting mu-opioid receptor antagonist...
AstraZeneca has announced that the New England Journal of Medicine has published results of two pivotal Phase III studies �...
The majority of FDA Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) members voted that the FDA should not require...
RedHill Biopharma Ltd. announced that it has entered into a binding term sheet with Cosmo Pharmaceuticals N.V. for an exclusive licensing and manufacturing agreement for multiple products.